WallStSmart

Novartis AG ADR (NVS)vsOwlet Inc (OWLT)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 50039% more annual revenue ($57.36B vs $114.41M). NVS leads profitability with a 17.5% profit margin vs -8.4%. NVS earns a higher WallStSmart Score of 48/100 (D+).

NVS

Hold

48

out of 100

Grade: D+

Growth: 4.0Profit: 9.0Value: 2.7Quality: 4.5
Piotroski: 4/9Altman Z: 1.96

OWLT

Hold

37

out of 100

Grade: F

Growth: 6.7Profit: 3.0Value: 5.0Quality: 6.0
Piotroski: 4/9Altman Z: -4.25
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

NVSSignificantly Overvalued (-68.3%)

Margin of Safety

-68.3%

Fair Value

$95.56

Current Price

$162.55

$66.99 premium

UndervaluedFair: $95.56Overvalued

Intrinsic value data unavailable for OWLT.

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

NVS4 strengths · Avg: 9.5/10
Market CapQuality
$303.67B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.3%10/10

Strong operational efficiency at 34.3%

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

OWLT2 strengths · Avg: 9.0/10
Debt/EquityHealth
0.0910/10

Conservative balance sheet, low leverage

Revenue GrowthGrowth
29.9%8/10

Revenue surging 29.9% year-over-year

Areas to Watch

NVS4 concerns · Avg: 4.0/10
P/E RatioValuation
30.7x4/10

Premium valuation, high expectations priced in

Price/BookValuation
8.2x4/10

Trading at 8.2x book value

Revenue GrowthGrowth
4.7%4/10

4.7% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

OWLT4 concerns · Avg: 2.8/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$121.85M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-526.0%2/10

ROE of -526.0% — below average capital efficiency

Free Cash FlowQuality
$-631,0002/10

Negative free cash flow — burning cash

Comparative Analysis Report

WallStSmart Research

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.

Bull Case : OWLT

The strongest argument for OWLT centers on Debt/Equity, Revenue Growth. Revenue growth of 29.9% demonstrates continued momentum.

Bear Case : NVS

The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.

Bear Case : OWLT

The primary concerns for OWLT are EPS Growth, Market Cap, Return on Equity.

Key Dynamics to Monitor

NVS profiles as a value stock while OWLT is a growth play — different risk/reward profiles.

OWLT carries more volatility with a beta of 2.22 — expect wider price swings.

OWLT is growing revenue faster at 29.9% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (48/100 vs 37/100), backed by strong 17.5% margins. Both earn "Hold" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Owlet Inc

HEALTHCARE · MEDICAL DEVICES · USA

Owlet Inc. is a leading innovator in infant health technology, dedicated to enhancing the safety and wellness of newborns through its state-of-the-art monitoring solutions. The company's flagship product, the Owlet Smart Sock, employs advanced pulse oximetry to provide parents with real-time insights into their infants' heart rates and oxygen levels via mobile devices. With growing demand for pediatric health monitoring solutions, Owlet is well-positioned to expand its product offerings and fortify its market presence. The company's focus on delivering actionable health information and improving pediatric care aligns with institutional investors' interests in the dynamic health technology sector.

Want to dig deeper into these stocks?